RESUMEN
This work evaluated circulating anti-SWAP IgG1 and IgG4 in patients with active S. mansoni infection before and after PZQ and its correlation to clinical, laboratory and sonographic data. The main complaints was abdominal discomfort, pain, tensmus and bleeding per rectum, which progressive decreased after PZQ. The anti-SWAP IgGI and IgG4 were significantly higher in patients than controls. A progressive significant decrease in the level of circulating anti-SWAP IgG1 after treatment, a decrease of IgG4 three months after treatment and a decrease in the egg count after therapy. But, no significant difference in IgG1 or IgG4 was noticed between male and female patients before and after treatment. No significant difference in IgGI or IgG4 in patients having GIT manifestation and organomegalic patients and/or asymptomatic patient. No significant difference in lgG1 or IgG4 between patients with grade (o), graele (I) and grade (II) periportal fibrosis. The sensitivity of ELISA IgGI was 73.3% and specificity was 80% while ELISA IgG4 was 80%. Enlarged liver and/or spleen, periportal fibrosis, and dilated P.V detected by ultrasonography were more among patients than controls. There was no significant difference in hematological parameters and liver function tests between patients and control groups. So, ELISA is sensitive and specific for IgG1 and IgG4. Anti-SWAP IgG1 and IgG4 is useful means in diagnosis and cure, as well as significant reduction of anti-SWAP IgG1 and IgG4 after treatment. Anti-SWAP IgG1 and IgG4 are parameter for evaluating cure. Follow up of anti-schistosomal IgG1 and IgG4 is useful for assessment of treatment
Asunto(s)
Antihelmínticos/uso terapéutico , Inmunoglobulina G/sangre , Praziquantel/uso terapéutico , Esquistosomiasis mansoni/tratamiento farmacológico , Esquistosomiasis mansoni/inmunología , Animales , Ensayo de Inmunoadsorción Enzimática , Heces/parasitología , Femenino , Humanos , Inmunoglobulina G/efectos de los fármacos , Masculino , Recuento de Huevos de Parásitos , Schistosoma mansoni/inmunología , Schistosoma mansoni/aislamiento & purificaciónRESUMEN
BACKGROUND: Duodenal ulcer (DU) is a common problem in patients with chronic liver disease (CLD) and with inadequate response to H2 receptor antagonists. Omeprazole might be more effective. In DU-CLD patients, Helicobacter pylori prevalence is low. Nitric oxide is increased in gastric mucosa in cirrhosis. Oxygen-free radicals have a role in gastric inflammation and are abnormal in CLD. Nitrotyrosine is a marker of nitric oxide and oxygen-free radical toxic mucosal reaction. METHODS: Sixty-nine patients were divided into 2 groups: control (26 patients with DU) and CLD groups (43 patients, DU-CLD). Omeprazole was given (40 mg/day) for 2 or 4 weeks. Symptoms and endoscopy findings were recorded before and after treatment. Antral biopsy specimens were stained for H. pylori and nitrotyrosine. RESULTS: Clinical features of DU are similar in patients with and without CLD. The main presentation was epigastric pain (70%) and bleeding (23%). Healing rate with omeprazole was higher in DU-CLD patients (90.7%) than in controls (80.8%). H. pylori was much lower in DU-CLD patients (51.2%) than controls (96.2%). Nitrotyrosine staining was negative in normal controls (0%) and positive in control-DU (100%), CLD-H. pylori positive (81%), and CLD-H. pylori negative (91%) cases. CONCLUSIONS: DU in patients with CLD is not different clinically from those without CLD. Omeprazole effectively and safely treats DU in CLD. Nitric oxide and free oxygen radicals may result in gastric mucosal changes in CLD similar to that caused by H. pylori.
Asunto(s)
Antiulcerosos/uso terapéutico , Úlcera Duodenal/complicaciones , Úlcera Duodenal/tratamiento farmacológico , Infecciones por Helicobacter/complicaciones , Infecciones por Helicobacter/epidemiología , Helicobacter pylori , Hepatopatías/complicaciones , Omeprazol/uso terapéutico , Adulto , Enfermedad Crónica , Femenino , Humanos , Hipertensión/complicaciones , Incidencia , Masculino , Persona de Mediana Edad , Estudios ProspectivosRESUMEN
Stimulation of esophageal nerves produces biphasic relaxation of the lower esophageal sphincter (LES) and an off response of circular esophageal muscle. Previously, we proposed that cGMP mediates nerve-induced hyperpolarization of circular LES muscle but not LES relaxation. These experiments explore whether cGMP mediates LES relaxation or the off response. Strips of muscle from the opossum esophagus and LES were connected to force-displacement transducers, placed in tissue baths containing oxygenated Krebs solution at 37 degrees C, and stimulated by an electrical field. 1H-[1,2, 4]oxadiazolo-[4,3-a]quinoxalin-1-one (ODQ), a selective inhibitor of guanylyl cyclase, antagonized the off response, shortened its latency, and blocked the first phase of LES relaxation. ODQ also antagonized LES relaxation by exogenous nitric oxide (NO) but not relaxations by vasoactive intestinal polypeptide (VIP). Part of the nerve-induced LES relaxation and the off response appear to be mediated by the second messenger cGMP. These studies indicate that VIP-induced LES relaxation is not mediated by cGMP and therefore do not support the hypothesis that VIP produces LES relaxation by causing the generation of NO.
Asunto(s)
GMP Cíclico/metabolismo , Unión Esofagogástrica/inervación , Unión Esofagogástrica/fisiología , Motilidad Gastrointestinal/fisiología , Animales , Atropina/farmacología , Sistema Nervioso Entérico/fisiología , Inhibidores Enzimáticos/farmacología , Femenino , Motilidad Gastrointestinal/efectos de los fármacos , Guanilato Ciclasa/antagonistas & inhibidores , Guanilato Ciclasa/metabolismo , Técnicas In Vitro , Masculino , Contracción Muscular/efectos de los fármacos , Contracción Muscular/fisiología , Fibras Musculares Esqueléticas/efectos de los fármacos , Fibras Musculares Esqueléticas/enzimología , Músculo Liso/citología , Músculo Liso/inervación , Músculo Liso/fisiología , Óxido Nítrico/metabolismo , Zarigüeyas , Oxadiazoles/farmacología , Parasimpatolíticos/farmacología , Quinoxalinas/farmacología , Péptido Intestinal Vasoactivo/metabolismoRESUMEN
Esophageal cancer is an increasingly common problem with poor survival rates in patients who present with symptoms. The underlying cause for the progressive rise in the incidence of this cancer remains to be determined. Reducing mortality to requires either early identification of patients or prevention for progression from Barrett's esophagus to cancer. Significant questions remain regarding the cost effectiveness of endoscopic and nonendoscopic methods of surveillance. For local esophageal cancer, the traditional approach has been surgical resection. Radiation therapy is sometimes used alone, but chemotherapy alone is not helpful. Combination therapy consisting of chemotherapy along with surgery or radiation may be the best choice. A new option being tried in disease limited to the mucosa is ablation of neoplastic tissue with endoscopic techniques. Treatment of advanced-stage esophageal cancer is limited and may be hampered by the presence of micrometastatic disease. Morbidity and quality-of-life issues need to be considered and discussed with patients, given the current short survival time of most patients with esophageal cancer.